Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study

Egeli B. H., Ergun S., Cetin A., Gursoy Y. K., UĞURLU S.

CLINICAL RHEUMATOLOGY, cilt.41, sa.1, ss.123-127, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s10067-021-05871-9
  • Dergi Adı: CLINICAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.123-127
  • Anahtar Kelimeler: Dermatomyositis, Polymyositis, Rituximab, POLYMYOSITIS, THERAPY, DERMATOMYOSITIS, EFFICACY
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background Idiopathic inflammatory myopathies (IIM) are essentially treated aiming to improve muscle function and extra muscular disease manifestations. Rituximab is potentially a glucocorticoid-sparing agent which was reviewed in multiple studies with small sample sizes due to the rarity of the disease. Higher statistical power can enhance the trustworthiness of alternative treatment modalities yielding the main objective of this study.